A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia

Autor: Oliva, Esther Natalie, Ronnebaum, Sarah M, Zaidi, Omer, Patel, Dipen A, Nehme, Salem Abi, Chen, Clara, Almeida, Antonio M

Publikováno v: Am J Blood Res

Acute myeloid leukemia (AML) is a rapidly progressive hematological malignancy that is difficult to cure. The prognosis is poor and treatment options are limited in case of relapse. A comprehensive assessment of current disease burden and the clinica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5495f7d5402224aca97c8136f6ef41f2
https://europepmc.org/articles/PMC8446831/

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.

Autor: Roboz GJ; Weill Cornell Medical College, New York, NY; New York Presbyterian Hospital, New York. gar2001@med.cornell.edu., Döhner H; Ulm University Hospital, Ulm., Pocock C; Kent and Canterbury Hospital, Canterbury., Dombret H; Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris (AP-HP) and Institut de Recherche Saint-Louis, Université de Paris, Paris., Ravandi F; The University of Texas MD Anderson Cancer Center, Houston., Jang JH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul., Selleslag D; AZ Sint-Jan Brugge-Oostende AV, Bruges., Mayer J; University Hospital Brno, Brno, Czech Republic., Martens UM; SLK-Kliniken GmbH, MOLIT Institute for Personalized Medicine, Heilbronn., Liesveld J; Wilmot Cancer Institute, University of Rochester, New York., Bernal T; Hospital Universitario Central de Asturias, Oviedo., Wang MC; Chang Gung Medical Foundation, Kaohsiung., Yu P; Evidera, Waltham., Shi L; Evidera, Waltham., Guo S; Evidera, Waltham., La Torre I; Celgene, a Bristol-Myers Squibb Company, Boudry., Skikne B; Bristol Myers Squibb, Princeton, NJ; University of Kansas Medical Center, Kansas City., Dong Q; Bristol Myers Squibb, Princeton., Braverman J; Bristol Myers Squibb, Princeton., Nehme SA; Celgene, a Bristol-Myers Squibb Company, Boudry., Beach CL; Bristol Myers Squibb, Princeton., Wei AH; The Alfred Hospital and Monash University, Melbourne.

Publikováno v: Haematologica [Haematologica] 2021 Dec 01; Vol. 106 (12), pp. 3240-3244. Date of Electronic Publication: 2021 Dec 01.